Non-Small Cell Lung Cancer (NSCLC)

The complete response letter for patritumab deruxtecan is based on findings related to a third-party manufacturing site inspection.

The approval for osimertinib/chemotherapy by the Japanese Pharmaceuticals and Medical Device Agency was based on results from the phase 3 FLAURA2 trial.

Disease-free survival did not show statistical significance for patients with early-stage non–small cell lung cancer treated with durvalumab.

Misako Nagasaka, MD, PhD, discussed the approval of amivantamab plus chemotherapy for patients with EGFR exon 20 insertion mutations non–small cell lung cancer.

A trial for BNT326/YL202 in EGFR-mutated NSCLC or HR-positive HER2-negative breast cancer has paused enrollment due to a large illness or injury risk.

Data from the phase 3 PALOMA study showed subcutaneous amivantamab had comparable ORR to intravenous administration for patients with EGFR-mutated NSCLC.

Tammy McClellan, PharmD, discusses the use of amivantamab plus chemotherapy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.

A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.

Data from the phase 3 ALINA trial support the approval of alectinib for patients with ALK-positive non–small cell lung cancer in the European Union.

The FDA is expected to decide on approving osimertinib for EGFR-mutated non–small cell lung cancer in the fourth quarter of 2024.

Lorlatinib may show “unprecedented” improvements in outcomes for those with advanced ALK-positive NSCLC, according to Benjamin J. Solomon, MBBS, PhD.

Data from the phase 1/2a AFM24-102 trial support the fast track designation for the AFM24 combination in EGFR wild-type non–small cell lung cancer.

The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.

Investigators plan to present additional findings from the phase 3 TROPION-Lung01 trial at a future medical meeting.

Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.

Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.

This segment discusses the details of the phase 3 randomized MARIPOSA-2 trial design evaluating amivantamab plus chemotherapy vs amivantamab, lazertinib and chemotherapy vs chemotherapy alone in osimertinib-resistant EGFR-mutant NSCLC.

This segment introduces a discussion on the MARIPOSA-2 trial evaluating amivantamab plus chemotherapy or amivantamab, lazertinib and chemotherapy in EGFR-mutant NSCLC after osimertinib progression.

The NEOpredict-Lung trial met its primary end point with nivolumab plus relatlimab for patients with resectable non–small cell lung cancer.

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.

Medical oncologists review updated data from the PAPILLON trial on amivantamab plus chemotherapy and discuss the treatment of patients with NSCLC with EGFR exon 20 insertions.

The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.

Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.

Estelamari Rodriguez, MD, MPH, presents a case of a 50-year-old African American woman, non-smoker, with pleural metastases; the panel discusses interstitial lung disease management, the use of antibody-drug conjugates, disease timing, and strategies for providing symptomatic relief, specifically considering drug holds if steroids only offer partial relief.

Christine Bestvina, MD, presents a case of a 34-year-old non-smoker diagnosed with Stage IIIA NSCLC after presenting with chest wall pain; the panel then explores their approaches to managing toxicities, including rashes and sores, by employing dose reductions and steroids to control adverse reactions.

Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.

Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.

Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.